e-learning
resources
Munich 2014
Sunday, 07.09.2014
Asthma and COPD devices and treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Safety of tiotropium in renally impaired patients
D. Tashkin, N. Metzdorf, C. Hallmann, M. Könen-Bergmann, K. Kupas, R. Dahl (Los Angeles, United States Of America; Ingelheim, Frankfurt, Germany; Odense, Denmark)
Source:
International Congress 2014 – Asthma and COPD devices and treatments
Session:
Asthma and COPD devices and treatments
Session type:
Thematic Poster Session
Number:
923
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Tashkin, N. Metzdorf, C. Hallmann, M. Könen-Bergmann, K. Kupas, R. Dahl (Los Angeles, United States Of America; Ingelheim, Frankfurt, Germany; Odense, Denmark). Safety of tiotropium in renally impaired patients. Eur Respir J 2014; 44: Suppl. 58, 923
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Is therapy adherence with inhaled tiotropium in COPD related to hospitalization, pneumonia or mortality?
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Cardio- and cerebrovascular safety of QVA149 in patients with moderate-to-severe COPD: A pooled analysis
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014
1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Once-daily tiotropium respimat add-on to ICS±LABA improves control across asthma severities
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Lung function improvements with twice-daily aclidinium/formoterol fixed-dose combination in two 24-week studies in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Is therapy adherence to inhaled corticosteroids related to hospitalization, pneumonia or mortality in COPD?
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Preference, satisfaction and critical errors with Genuair
®
and Breezhaler
®
in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Experience with omalizumab in patients with moderate and severe asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Efficacy and safety of indacaterol acetate on ICS background therapy in asthma
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Frequency of COPD exacerbations in the real-life out-patient DACCORD cohort
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
Safety of once-daily glycopyrronium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Prognostic factors of mortality and cardiovascular outcomes in the tiotropium safety and performance in respimat (TIOSPIR) trial
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept